In Vaccines, PhRMA Celebrates Challenges As Much As Success
Executive Summary
At the organization’s Research and Hope Awards, the academics won for products that are already on the market, and the pharmaceutical company won for the vaccine that’s still in development.
You may also be interested in...
GSK Prepares For Malaria Vaccine Roll-Out In Africa By 2015
“While we have seen some decline in vaccine efficacy over time, the sheer number of children affected by malaria means that the number of cases of the disease the vaccine can help prevent is impressive,” GSK CEO Witty says.
PhRMA’s Revamped Research Awards Aim To Encourage Alzheimer’s “Ecosystem”
Shifting the program from the Discoverers Award, which focused solely on industry achievements, to broader honors acknowledges that “finding the Alzheimer's treatment that works is a tremendous task” which requires “collaboration with our partners” in the scientific and patient advocacy communities, PhRMA President Castellani says.
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.